ReviewMultiple sclerosis (Houndmills, Basingstoke, England)2012
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS.
Review in Multiple sclerosis (Houndmills, Basingstoke, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03896217 (A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- The CogEx trial - Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis: A randomised, blinded, sham-controlled trial.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Trial
- Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2018Trial
- Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.Contemporary clinical trials · 2016Trial
- Needs, experiences, and knowledge of people with primary progressive multiple sclerosis: a scoping review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Neurofilament heavy chain in secondary progressive multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Article
- Article
- The impact of the COVID-19 pandemic on an international rehabilitation study in MS: the CogEx experience.Journal of neurology · 2022Article
- JAB1 deletion in oligodendrocytes causes senescence-induced inflammation and neurodegeneration in mice.The Journal of clinical investigation · 2022Article
- Role of artificial intelligence in MS clinical practice.NeuroImage. Clinical · 2022Review
- Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Review
- Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposal.Nature reviews. Neurology · 2021Review
- Stem Cell Therapies for Progressive Multiple Sclerosis.Frontiers in cell and developmental biology · 2021Review
- Advanced Multicompartment Diffusion MRI Models and Their Application in Multiple Sclerosis.AJNR. American journal of neuroradiology · 2020Review
- Selective inversion recovery quantitative magnetization transfer imaging: Toward a 3 T clinical application in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Article
- Article
- The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms.Frontiers in neurology · 2020Article
- Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression.Neurology and therapy · 2019Article
- Palliative care interventions for people with multiple sclerosis.The Cochrane database of systematic reviews · 2019Review
- Probing axons using multi-compartmental diffusion in multiple sclerosis.Annals of clinical and translational neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Despite significant progress in the development of therapies for relapsing MS, progressive MS remains comparatively disappointing. Our objective, in this paper, is to review the current challenges in developing therapies for progressive MS and identify key priority areas for research. A collaborative was convened by volunteer and staff leaders from several MS societies with the mission to expedite the development of effective disease-modifying and symptom management therapies for progressive forms of multiple sclerosis. Through a series of scientific and strategic planning meetings, the collaborative identified and developed new perspectives on five key priority areas for research: experimental models, identification and validation of targets and repurposing opportunities, proof-of-concept clinical trial strategies, clinical outcome measures, and symptom management and rehabilitation. Our conclusions, tackling the impediments in developing therapies for progressive MS will require an integrated, multi-disciplinary approach to enable effective translation of research into therapies for progressive MS. Engagement of the MS research community through an international effort is needed to address and fund these research priorities with the ultimate goal of expediting the development of disease-modifying and symptom-relief treatments for progressive MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.